Rhabdomyosarcoma is a type of cancer that forms in the body's soft tissues. This study is testing treatments for patients with very low-risk (VLR) and low-risk (LR) rhabdomyosarcoma who do not have a specific gene change called fusion negative. The study aims to maintain good results with less treatment for VLR patients using 24 weeks of chemotherapy drugs called vincristine and dactinomycin. It also aims to find out how well patients with LR respond to a mix of chemotherapy treatments. For patients with specific DNA mutations, the study tests if more intense treatment helps improve outcomes.

• Study involves 24 weeks of treatment for VLR and a mix of 12 weeks each for LR.
• Study requires blood and tissue samples and regular scans like CT (computed tomography) and MRI (magnetic resonance imaging).
• Participants must be 21 or younger and have specific types of rhabdomyosarcoma.

Participants should talk to their doctor about the potential risks and benefits of joining the study and whether it fits their situation.